← All Theriva Biologics, INC filings

Theriva Biologics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
TOVX
Theriva Biologics, INC
10-K: Theriva Biologics Reports Positive Cancer Trial, Strategic Shift
Theriva Biologics announced positive Phase 2b pancreatic cancer trial results for VCN-01 and a strategic shift to focus on oncology, while licensing out its SYN-020 asset.
AMEX
TOVX
Theriva Biologics, INC
10-K: Theriva Biologics Reports 2024 Results, Focuses on Oncolytic Virus Pipeline
Theriva Biologics transitions strategic focus to oncology, developing oncolytic adenovirus platform while exploring options for gastrointestinal assets.
AMEX
TOVX
Theriva Biologics, INC
10-K: Theriva Biologics Details Share Structure and Anti-Takeover Measures in 10-K Filing
Theriva Biologics outlines its common stock characteristics, voting rights, and anti-takeover provisions in its latest 10-K filing.